Jefferies Sticks to Its Buy Rating for AveXis Inc

By Carrie Williams

Jefferies analyst Eun Yang reiterated a Buy rating on AveXis Inc (NASDAQ: AVXS) yesterday and set a price target of $92. The company’s shares closed yesterday at $72.55.

According to, Yang is a 4-star analyst with an average return of 2.9% and a 48.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on AveXis Inc is Strong Buy and the average price target is $96.25, representing a 32.7% upside.

In a report issued on May 23, Citigroup also initiated coverage with a Buy rating on the stock with a $90 price target.

The company has a one year high of $85.98 and a one year low of $31.55. Currently, AveXis Inc has an average volume of 438.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.